Menta Capital LLC Decreases Stake in Enzymotec Ltd. (ENZY)
Menta Capital LLC lowered its position in Enzymotec Ltd. (NASDAQ:ENZY) by 17.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,869 shares of the biotechnology company’s stock after selling 4,187 shares during the period. Menta Capital LLC owned 0.09% of Enzymotec worth $161,000 as of its most recent SEC filing.
Enzymotec Ltd. (NASDAQ ENZY) opened at 11.45 on Friday. The stock has a 50 day moving average price of $11.35 and a 200 day moving average price of $9.14. The company’s market cap is $262.77 million. Enzymotec Ltd. has a 12 month low of $5.20 and a 12 month high of $12.35.
Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.15). The firm had revenue of $13.00 million during the quarter, compared to analysts’ expectations of $12.78 million. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.04 EPS. Analysts anticipate that Enzymotec Ltd. will post $0.14 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/menta-capital-llc-decreases-stake-in-enzymotec-ltd-enzy/1612017.html.
Separately, ValuEngine raised Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Want to see what other hedge funds are holding ENZY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzymotec Ltd. (NASDAQ:ENZY).
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.